Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer.
Their transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology.
Their mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.
Privately-held Immatics was established in 2000 as a spin out from H.G. Rammensee's laboratory at the University of Tübingen, Germany. The Company was founded to develop and commercialize ground-breaking discoveries on the immunopeptidome as targets for all types of T-cell based immunotherapies.
In 2015, Immatics and MD Anderson Cancer Center (MDACC) launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.See more